Quantification of Neurological Blood-Based Biomarkers in Critically Ill Patients With Coronavirus Disease 2019.
coronavirus disease 2019
delirium
glial fibrillary acidic protein
neurofilament-light
severe acute respiratory syndrome coronavirus-2
Journal
Critical care explorations
ISSN: 2639-8028
Titre abrégé: Crit Care Explor
Pays: United States
ID NLM: 101746347
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
entrez:
16
10
2020
pubmed:
17
10
2020
medline:
17
10
2020
Statut:
epublish
Résumé
To provide an objective characterization of acute neurologic injury in critically ill patients with coronavirus disease 2019. Prospective observational study. Demographics, comorbidities, and daily clinical physiologic and laboratory data were collected. Plasma levels of neurofilament-light chain, total tau, ubiquitin carboxy-terminal hydrolase L1, and glial fibrillary acidic protein were measured. The primary neurologic outcome was delirium defined by the Intensive Care Delirium Screening Checklist (scale 1-8). Associations among plasma biomarkers, respiratory failure, and inflammation were analyzed. Multicenter study in ICUs. Critically ill patients with respiratory failure, with coronavirus disease 2019, or without (ICU control). A total of 27 patients with coronavirus disease 2019 and 19 ICU controls were enrolled. Compared with ICU controls with pneumonia of other etiology, patients with coronavirus disease 2019 had significantly higher glial fibrillary acidic protein (272 pg/mL [150-555 pg/mL] vs 118 pg/mL [78.5-168 pg/mL]; Plasma glial fibrillary acidic protein is two-fold higher in critically ill patients with coronavirus disease 2019 compared with ICU controls. Higher levels of glial fibrillary acidic protein, ubiquitin carboxy-terminal hydrolase L1, and neurofilament-light chain associate with delirium in patients with coronavirus disease 2019. Elevated plasma glial fibrillary acidic protein, ubiquitin carboxy-terminal hydrolase L1, and neurofilament-light chain are independent of respiratory function and peripheral cytokines.
Identifiants
pubmed: 33063038
doi: 10.1097/CCE.0000000000000238
pmc: PMC7535554
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e0238Informations de copyright
Copyright © 2020 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine.
Déclaration de conflit d'intérêts
The authors have disclosed that they do not have any potential conflicts of interest.
Références
N Engl J Med. 2020 Aug 6;383(6):590-592
pubmed: 32402155
Neurology. 2020 Sep 22;95(12):e1754-e1759
pubmed: 32546655
Viruses. 2019 Dec 20;12(1):
pubmed: 31861926
Alzheimers Res Ther. 2020 May 13;12(1):56
pubmed: 32404143
Lancet Respir Med. 2018 Mar;6(3):213-222
pubmed: 29508705
J Med Virol. 2020 Apr 28;:
pubmed: 32343429
Crit Care. 2020 Apr 28;24(1):176
pubmed: 32345343
Neurology. 2016 Oct 25;87(17):1827-1835
pubmed: 27694257
J Neurol Neurosurg Psychiatry. 2019 Aug;90(8):870-881
pubmed: 30967444
Eur J Neurol. 2020 Aug;27(8):1578-1587
pubmed: 32416028
J Neurol Sci. 2020 Jun 15;413:116832
pubmed: 32299017
J Neurol. 2020 Aug;267(8):2179-2184
pubmed: 32458193
Lancet. 2007 Oct 20;370(9596):1453-7
pubmed: 18064739
Radiology. 2020 Oct;297(1):E232-E235
pubmed: 32384020
Life Sci. 2020 Aug 15;255:117839
pubmed: 32450165
Intensive Care Med. 2001 May;27(5):859-64
pubmed: 11430542
Eur J Neurol. 2020 Apr 25;:
pubmed: 32333487
ACS Chem Neurosci. 2020 Apr 1;11(7):995-998
pubmed: 32167747
Nat Rev Neurol. 2016 Oct;12(10):563-74
pubmed: 27632903
Mol Cell Neurosci. 2015 May;66(Pt B):99-102
pubmed: 25659491
CNS Neurosci Ther. 2020 May;26(5):499-501
pubmed: 32266761
Am J Crit Care. 2017 Nov;26(6):447-455
pubmed: 29092867
Brain Behav Immun. 2020 Jul;87:115-119
pubmed: 32360439
Trends Neurosci. 2015 Jun;38(6):364-74
pubmed: 25975510
Sci Rep. 2019 May 9;9(1):7177
pubmed: 31073130
JAMA Neurol. 2020 Jun 1;77(6):683-690
pubmed: 32275288
J Neurol Neurosurg Psychiatry. 2016 Feb;87(2):126-9
pubmed: 25716934